SNMMI Consensus Statement on Patient Selection and Appropriate Use of<sup>177</sup>Lu-PSMA-617 Radionuclide Therapy
Thomas A. Hope, Emmanuel S. Antonarakis, Lisa Bodei, Jérémie Calais, Amir Iravani, Heather A. Jacene, Phillip J. Koo, Alicia K. Morgans, Joseph R. Osborne, Scott T. Tagawa, Mary‐Ellen Taplin, Oliver Sartor, Michael J. Morris
Abstract
Prostate-specific membrane antigen (PSMA) is a transmembrane carboxypeptidase that is highly expressed in prostate cancer. Radioligand therapy (RLT) with 177Lu-labeled compounds has shown clinical benefit, and the U.S. Food and Drug Administration (FDA) approved 177Lu-PSMA-617 (177Lu-vipivotide
Topics & Concepts
Glutamate carboxypeptidase IIRadioligandRadionuclide therapyFood and drug administrationProstate cancerMedicineNuclear medicineChemistryOncologyInternal medicinePharmacologyCancerReceptorProstate Cancer Treatment and ResearchRadiopharmaceutical Chemistry and ApplicationsCancer-related gene regulation